| Similar Articles |
|---|
 |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.   |
The Motley Fool
May 11, 2011
Brian Orelli |
Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good. |
The Motley Fool
May 19, 2010
Brian Orelli |
A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
June 30, 2009
Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
June 12, 2008
Brian Orelli |
Schering-Plough and J&J Score a Triple-Triple Schering-Plough and Johnson & Johnson present three phase 3 trials for a single drug, their anti-TNF medication golimumab. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
August 7, 2009
Brian Orelli |
A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court. |
The Motley Fool
July 9, 2009
Brian Orelli |
Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
April 27, 2009
Brian Orelli |
Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
January 16, 2008
Brian Lawler |
More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note. |
The Motley Fool
April 15, 2011
Brian Orelli |
Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
September 30, 2009
Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
October 11, 2010
Brian Orelli |
A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer. |
The Motley Fool
November 21, 2007
Brian Lawler |
Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note. |
The Motley Fool
January 27, 2010
Brian Orelli |
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
April 15, 2009
Brian Orelli |
Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
April 17, 2008
Brian Orelli |
Abbott's Not Ailing Abbott produces double-digit growth; investors yawn. |
The Motley Fool
July 23, 2007
Brian Lawler |
A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease. |
The Motley Fool
December 26, 2007
Brian Orelli |
Inflamed Anti-Inflammatory Contract Revised J&J and Schering revise their agreement over anti-TNF compounds. |
The Motley Fool
May 21, 2009
Brian Orelli |
Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
June 17, 2004
Brian Gorman |
Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
Chemistry World
September 11, 2013
Phillip Broadwith |
First biosimilar antibody drugs approved in Europe The European commission has given final marketing approval to the first generic versions of monoclonal antibody drug infliximab (Johnson & Johnson's Remicade). |
The Motley Fool
September 8, 2008
Brian Orelli |
Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
September 3, 2009
Brian Orelli |
Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
The Motley Fool
February 24, 2011
Brian Orelli |
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
